University of Toronto Lawrence Bloomberg Faculty of Nursing, Toronto, Ontario, Canada.
Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada.
BMJ Paediatr Open. 2024 Jul 10;8(1):e002604. doi: 10.1136/bmjpo-2024-002604.
Oral sucrose is repeatedly administered to neonates in the neonatal intensive care unit (NICU) to treat pain from commonly performed procedures; however, there is limited evidence on its long-term cumulative effect on neurodevelopment. We examined the association between total sucrose volumes administered to preterm neonates for pain mitigation in the NICU and their neurodevelopment at 18 months of corrected age (CA).
A prospective longitudinal single-arm observational study that enrolled hospitalised preterm neonates <32 weeks of gestational age at birth and <10 days of life was conducted in four level III NICUs in Canada. Neonates received 0.1 mL of 24% sucrose 2 min prior to all commonly performed painful procedures during their NICU stay. Neurodevelopment was assessed at 18 months of CA using the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III). Multiple neonatal and maternal factors known to affect development were adjusted for in the generalised linear model analysis.
172 preterm neonates were enrolled and 118 were included in the analysis at 18 months of CA. The total mean sucrose volume administered/neonate/NICU stay was 5.96 (±5.6) mL, and the mean Bayley-III composite scores were: cognitive 91 (±17), language 86 (±18) and motor 88 (±18). There was no association between Bayley-III scores and the total sucrose volume: cognitive (p=0.57), language (p=0.42) and motor (p=0.70).
Cumulative sucrose exposure for repeated procedural pain in preterm neonates was neither associated with a delay in neurodevelopment nor neuroprotective effects at 18 months of CA. If sucrose is used, we suggest the minimally effective dose combined with other non-pharmacological interventions with demonstrated effectiveness such as skin-to-skin contact, non-nutritive sucking, facilitated tucking and swaddling.
NCT02725814.
在新生儿重症监护病房(NICU)中,反复给新生儿口服蔗糖以缓解常见操作引起的疼痛;然而,关于其对神经发育的长期累积影响的证据有限。我们研究了在 NICU 中为缓解早产儿疼痛而给予的总蔗糖量与他们在纠正胎龄(CA)18 个月时的神经发育之间的关系。
这是一项前瞻性纵向单臂观察性研究,在加拿大的四个 3 级 NICU 中纳入了出生时胎龄<32 周且<10 天的住院早产儿。在 NICU 期间,所有常见的疼痛操作前 2 分钟,新生儿均给予 0.1 mL 24%蔗糖。在 CA 18 个月时,使用贝利婴幼儿发育量表,第三版(Bayley-III)进行神经发育评估。在广义线性模型分析中,调整了已知影响发育的多种新生儿和产妇因素。
纳入了 172 名早产儿,其中 118 名在 CA 18 个月时纳入分析。每个新生儿在 NICU 期间接受的平均总蔗糖量为 5.96(±5.6)mL,Bayley-III 综合评分分别为:认知 91(±17)、语言 86(±18)和运动 88(±18)。Bayley-III 评分与总蔗糖量之间无相关性:认知(p=0.57)、语言(p=0.42)和运动(p=0.70)。
在 CA 18 个月时,早产儿反复接受程序性疼痛治疗时蔗糖暴露的累积量与神经发育延迟或神经保护作用无关。如果使用蔗糖,我们建议使用最小有效剂量,同时结合其他非药物干预措施,如皮肤接触、非营养性吸吮、促进包裹和襁褓等,这些措施已被证明是有效的。
NCT02725814。